The Breadth of PD(L)1 Development in 2021

Data from CancerMPact® highlight the extent of PD(L)1 development across tumors of widely varying unmet need.

Development of immuno-oncology drugs has risen dramatically over the last decade. With 6 PD(L)1 agents now FDA approved, development now extends across numerous tumor types. In particular, tumors with poor prognoses (based on 5-year survival) and large patient populations (based on treatable 1st-line patients), such as Non-Small Cell Lung Cancer and Bladder Cancer, have seen significant success. Yet in others, like Pancreatic Cancer and Glioblastoma, development and/or successful outcomes have been limited.

CancerMPact: Improving outcomes through empowered decision making. Start or continue your journey here.

Data is up to date as of February 2021. Hover for more information.